公开(公告)号：WO1996039871A1

公开(公告)日：1996-12-19

申请号：PCT/US1996008214

申请日：1996-05-31

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GOLIGHTLY, Danold, Wayne ,  SGONTZ, Donald, Lee, Jr. ,  KEDZIERSKI, Bogdan, Kazimierz ,  ABEL, Frank, Stanley ,  YAO, Benita, Co

IPC: A23L01/304

CPC classification number: A23L33/165

Abstract: Process methods are described for combining compounds of mineral nutrients into chemically stable powder mixtures that notably preserve chromium in a soluble form conducive to both absorption and bioavailability. The methods include the compounds of minerals in preferred chemical forms, procedures for treatment of certain compounds to maintain solubility, appropriate sequences for combination of the compounds and other premix ingredients, and blending to provide an adequately homogeneous mixture. The methods provide premixes of minerals that support bioavailable chromium and that exhibit good stability, solubility, odor and color for addition to nutritional products. The stable chronium -III- complexes are prepared by complexing a Cr-III powder with a carboxylic acid. The nutritional powdered mixture comprises water to substantially resist formation of insoluble chronium compounds.

Abstract translation: 描述了将矿物营养物的化合物组合成化学稳定的粉末混合物的方法，其特别是以可吸收的形式保存铬，这有助于吸收和生物利用度。 这些方法包括优选化学形式的矿物化合物，用于处理某些化合物以保持溶解性的方法，用于组合化合物和其它预混物成分的合适顺序，以及混合以提供足够均匀的混合物。 该方法提供了支持生物可利用铬的矿物质的预混物，并且对营养产品的添加表现出良好的稳定性，溶解性，气味和颜色。 通过使Cr-III粉末与羧酸络合来制备稳定的时间-III-络合物。 营养粉末混合物包含水以基本上抵抗不溶性时代化合物的形成。

公开(公告)号：WO1996039407A1

公开(公告)日：1996-12-12

申请号：PCT/US1996008991

申请日：1996-06-05

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  CHU, Daniel, T. ,  LI, Qun ,  COOPER, Curt, S. ,  FUNG, Anthony, K., L. ,  LEE, Cheuk, M. ,  PLATTNER, Jacob, J. ,  MA, Zhenkun ,  WANG, Wei-Bo

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K38/00 ,  C07D213/61 ,  C07D213/68 ,  C07D455/02 ,  C07K5/06026

Abstract: Antibacterial compounds having formula (I) and the pharmaceutically acceptable salts, esters and amides thereof, selected preferred examples of which include those compounds wherein A is =CR -; R is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R is selected from the group consisting of (a), (b), (c) and (d); R is halogen; R is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R is hydrogen, loweralkyl, halo(loweralkyl), or -NR R ; and R is halogen, loeralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

Abstract translation: 具有式（I）的抗菌化合物及其药学上可接受的盐，酯和酰胺，其选择的优选实例包括其中A = CR 6 - 的那些化合物; R 1是3至8个碳原子的环烷基或取代的苯基; R 2选自（a），（b），（c）和（d）; R 3是卤素; R 4是氢，低级烷基，药学上可接受的阳离子或前药酯基; R 5是氢，低级烷基，卤代（低级烷基）或-NR 13 R 14; 和R 6是卤素，低级烷基，卤代（低级烷基），羟基取代的低级烷基，低级烷氧基（低级烷基），低级烷氧基或氨基（低级烷基），以及含有这些化合物的药物组合物及其在治疗中的用途 的细菌感染。

公开(公告)号：WO1996039037A1

公开(公告)日：1996-12-12

申请号：PCT/US1996007807

申请日：1996-05-30

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MANKER, Denise, C. ,  LIDSTER, William, D. ,  MACINTOSH, Susan, C. ,  STARNES, Robert, L.

IPC: A01N63/02

CPC classification number: A01N47/28 ,  A01N63/02

Abstract: This invention is directed to a method for obtaining a factor which potentiates the pesticidal activity of a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties.

Abstract translation: 本发明涉及一种用于获得增强具有杀虫特性的芽孢杆菌相关农药，化学农药和/或病毒的杀虫活性的因素的方法。

公开(公告)号：WO1996036736A2

公开(公告)日：1996-11-21

申请号：PCT/US1996007138

申请日：1996-05-17

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  SOLOMON, Natalie, A. ,  BOUMA, Stanley, R.

IPC: C12Q01/68

CPC classification number: C12Q1/6851 ,  C12Q1/6834 ,  C12Q1/6862 ,  C12Q1/703 ,  C12Q1/706 ,  C12Q2537/143 ,  C12Q2527/143

Abstract: The present invention provides a method of detecting the amount of a target sequence which may be present in a test sample. The method uses an aggregate primer series, which comprises at least two primer sets, in an amplification reaction to detect the relative concentration of a target sequence which may be present in a test sample. The primer sets have different sensitivities and hybridize with sub-target sequences which are different regions of the target sequence. The method generally comprises cycling a test sample suspected of containing a target sequence, an aggregate primer series, and means necessary for performing an amplification reaction; and detecting any amplified sub-target sequences. Based on a qualitative detection of the amplified sub-target sequences generated by individual primer sets, the relative quantity of the target sequence can be determined.

Abstract translation: 本发明提供了检测可能存在于测试样品中的靶序列的量的方法。 该方法在扩增反应中使用包含至少两个引物组的聚集引物序列，以检测可能存在于测试样品中的靶序列的相对浓度。 引物组具有不同的灵敏度并与靶序列的不同区域的亚靶序列杂交。 该方法通常包括循环怀疑含有靶序列的测试样品，聚集引物序列和进行扩增反应所需的手段; 并检测任何扩增的亚靶序列。 基于由各引物组产生的扩增子靶序列的定性检测，可以确定目标序列的相对量。

公开(公告)号：WO1996036722A2

公开(公告)日：1996-11-21

申请号：PCT/US1996006841

申请日：1996-05-14

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MAINE, Gregory, T. ,  CHOVAN, Linda, E.

IPC: C12N15/72

CPC classification number: C12N15/72 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/62 ,  C12N2710/16122

Abstract: A method for expressing a heterologous protein in a prokaryotic host cell, comprising the steps of: (a) providing a DNA vector having: (1) a control region operatively linked to a first genetic element encoding a carrier protein capable of expression in the host cell, and (2) a second genetic element encoding the heterologous protein, the second element being embedded within the first element such that the first and second elements are contiguous and in the same reading frame; (b) transforming the host cell with the DNA vector; and (c) expressing a fusion protein of the heterologous protein and the carrier protein, wherein the heterologous protein is joined at its N-terminus to a first domain of the carrier protein and at its C-terminus to a second domain of the carrier protein, and also a method for confirming intact expression of heterologous proteins, as well as fusion proteins, DNA constructs, plasmid vectors and transformed host cells relating to the above methods.

Abstract translation: 一种用于在原核宿主细胞中表达异源蛋白质的方法，包括以下步骤：（a）提供DNA载体，所述DNA载体具有：（1）与编码能够在宿主中表达的载体蛋白的第一遗传元件可操作地连接的对照区 细胞，和（2）编码异源蛋白质的第二遗传元件，第二元素嵌入在第一元素内，使得第一和第二元素连续并且位于相同的阅读框中; （b）用DNA载体转化宿主细胞; 和（c）表达异源蛋白质和载体蛋白质的融合蛋白，其中所述异源蛋白质在其N末端连接至载体蛋白质的第一结构域，并且其C末端连接至载体蛋白质的第二结构域 ，以及用于确认异源蛋白质的完整表达以及与上述方法相关的融合蛋白，DNA构建体，质粒载体和转化的宿主细胞的方法。

公开(公告)号：WO1996034851A1

公开(公告)日：1996-11-07

申请号：PCT/US1996006193

申请日：1996-05-02

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BAKER, William, R. ,  ROSENBERG, Saul, H. ,  FUNG, K., L., Anthony ,  ROCKWAY, Todd, W. ,  FAKHOURY, Stephen, A. ,  GARVEY, David, S. ,  DONNER, B., Gregory ,  O'CONNOR, Stephen, J. ,  PRASAD, Rajnandan, N. ,  SHEN, Wang ,  STOUT, David, M. ,  SULLIVAN, Gerard, M.

IPC: C07C233/73

CPC classification number: C07D213/40 ,  C07C65/24 ,  C07C65/28 ,  C07C65/40 ,  C07C69/94 ,  C07C229/38 ,  C07C233/22 ,  C07C233/65 ,  C07C233/69 ,  C07C233/73 ,  C07C233/87 ,  C07C235/16 ,  C07C235/34 ,  C07C235/42 ,  C07C235/48 ,  C07C235/60 ,  C07C235/84 ,  C07C237/08 ,  C07C237/20 ,  C07C237/32 ,  C07C251/48 ,  C07C255/57 ,  C07C259/10 ,  C07C271/48 ,  C07C275/42 ,  C07C311/08 ,  C07C311/29 ,  C07C311/51 ,  C07C323/59 ,  C07C327/48 ,  C07C333/04 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/18 ,  C07C2603/74 ,  C07D209/16 ,  C07D231/12 ,  C07D271/113 ,  C07D307/88 ,  C07D307/89 ,  C07D309/32 ,  C07D311/68 ,  C07D319/06 ,  C07D333/20

Abstract: The present invention provides a compound of formula (I), (II), (III) or (IV), processes for the preparation of the compounds of the invention, intermediates useful in these processes, a pharmaceutical composition, and methods of using the compounds of the invention.

Abstract translation: 本发明提供式（I），（II），（III）或（IV）的化合物，制备本发明化合物的方法，可用于这些方法的中间体，药物组合物和使用 本发明的化合物。

公开(公告)号：WO1996032377A1

公开(公告)日：1996-10-17

申请号：PCT/US1996003907

申请日：1996-03-22

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BROOKS, Clint, D., W. ,  STEWART, Andrew, O. ,  BASHA, Anwer ,  BELL, Randy, L.

IPC: C07C275/64

CPC classification number: C07D409/12 ,  C07C275/64 ,  C07D307/52 ,  C07D333/20 ,  C07D333/58

Abstract: Compounds having the structure of general formula (I) or a pharmaceutically acceptable salt thereof have activity as inhibitors of cyclooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B4, C4, D4, and E4 and cyclooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optionally susbtituted carbocyclic aryl, (b) optionally substituted furyl, (c) optionally substituted benzo[b]furyl, (d) optionally substituted thienyl, (e) optionally substituted pyridyloxy, (f) optionally substituted pyridylalkyl, (g) optionally substituted benzo[b]thienyl, (h) optionally substituted pyridyl, (i) optionally substituted quinolyl, and (j) optionally substituted indolyl; X is selected from (a) optionally susbtituted alkyl, (b) optionally substituted alkenyl, and (c) optionally substituted alkynyl; R and R are independently selected from hydrogen, hydroxy, and alkyl; and Z is a residue of a non-steroidal anti-inflammatory drug of the general formula Z-COOH.

Abstract translation: 具有通式（I）结构的化合物或其药学上可接受的盐具有作为环加氧酶和5-脂氧合酶抑制剂的活性，降低了白三烯B4，C4，D4和E4以及环氧合酶产物如前列腺素和血栓素的生物合成， 可用于治疗炎症和过敏性疾病状态。 化合物具有上述结构，其中A选自（a）任选取代的碳环芳基，（b）任选取代的呋喃基，（c）任选取代的苯并[b]呋喃基，（d）任选取代的噻吩基，（e） 吡啶基氧基，（f）任选取代的吡啶基烷基，（g）任选取代的苯并[b]噻吩基，（h）任选取代的吡啶基，（i）任选取代的喹啉基，和（j）任选取代的吲哚基; X选自（a）任选的取代的烷基，（b）任选取代的烯基，和（c）任选取代的炔基; R 1和R 2独立地选自氢，羟基和烷基; Z为通式Z-COOH的非甾体抗炎药物的残基。

公开(公告)号：WO1996031219A1

公开(公告)日：1996-10-10

申请号：PCT/US1996004665

申请日：1996-04-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GARLEB, Keith, Allen ,  WOLF, Brian, Warren ,  MEULBROEK, Jonathan, Allan ,  WHEELER, Keith, Brian ,  CAMPBELL, Shelia, Martinson ,  WALTON, Joseph, Edward

IPC: A61K31/70

CPC classification number: A61K31/7016 ,  A61K31/702 ,  A61K33/14 ,  A61K33/00 ,  A61K31/70 ,  A61K2300/00

Abstract: The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs; and dehydration due to diarrhea is an exacerbating problem. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection. An oral rehydration solution containing such indigestible oligosaccharides also provides fluid and electrolyte replacement.

Abstract translation: 抗生素相关性腹泻（也称为假膜性结肠炎）的主要病因已经被认为是艰难梭菌。 据信，健康个体的土着微生物群落抑制了正常存在的艰难梭菌。 然而，当土着微生物群落被破坏时（例如，在抗生素治疗期间），可能发生艰难梭菌的过度生长，导致腹泻和结肠炎。 用抗生素治疗艰难梭菌已被证明是有效的，但多次发生复发; 而由于腹泻引起的脱水是一个加剧的问题。 有人认为微生物群落的正常化会抑制艰难梭菌的复发。 已经显示难消化的寡糖抑制艰难梭菌感染。 包含这种难消化的寡糖的口服补液溶液也提供流体和电解质替代物。

公开(公告)号：WO1996031130A2

公开(公告)日：1996-10-10

申请号：PCT/US1996004601

申请日：1996-04-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MAZER, Terrence, Bruce ,  DEWILLE, Normanella, Torres ,  CHANDLER, Michael, Allen ,  RAGAN, Robert, John ,  SNOWDEN, Gregory, Allan ,  GERAGHTY, Maureen, Elizabeth ,  JOHNSON, Catherine, Dubinin ,  DRAYER, Lonnie, Richard

IPC: A23L01/303

CPC classification number: A61K33/06 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/59 ,  A61K31/375 ,  A61K2300/00 ,  A23V2250/7106 ,  A23V2250/708 ,  A23V2250/154 ,  A23V2250/1578 ,  A23V2250/5028 ,  A23V2250/21 ,  A23V2250/032 ,  A23V2250/042 ,  A23V2250/2482 ,  A23V2250/70 ,  A23V2250/11

Abstract: The present invention relates to calcium supplements and, in particular, to a solid supplement fortified with calcium glycerophosphate, vitamin D, vitamin C, vegetable oil and a gum selected from the group consisting of gum arabic, gum tragacanth and xanthan gum; to a beverage concentrate or additive (liquid or powder) containing calcium, vitamin D, a vegetable oil and a gum; and to a beverage made by reconstituting such beverage concentrates and additives to make a liquid nutritional product fortified with both calcium and vitamin D, and preferably having a low pH. Concentrates may be diluted with water or juices.

Abstract translation: 本发明涉及钙补充剂，特别涉及用甘油磷酸钙，维生素D，维生素C，植物油和选自阿拉伯树胶，西黄蓍胶和黄原胶的组合物强化的固体补充剂; 包含钙，维生素D，植物油和树胶的饮料浓缩物或添加剂（液体或粉末）; 以及通过重构这种饮料浓缩物和添加剂制成的饮料，以制备用钙和维生素D加强的液体营养产品，并且优选具有低pH值。 浓缩物可能会用水或果汁稀释。

公开(公告)号：WO1996027017A1

公开(公告)日：1996-09-06

申请号：PCT/US1996002623

申请日：1996-02-27

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MUKERJI, Pradip ,  THURMOND, M., Jennifer ,  HANSSON, L., Stig

IPC: C12N15/64

CPC classification number: C12N9/12 ,  A61K38/00 ,  C07K14/4732 ,  C07K2319/02 ,  C12N15/62 ,  C12N15/64 ,  C12N15/70

Abstract: The present invention provides a method of producing a modified recombinant protein in a host cell using a single vector containing in tandem both the nucleotide sequence encoding an exogenous protein and an enzyme specific for modification of that protein. The invention also specifically provides a method of producing a recombinant phosphorylated human protein in a bacterial system using a single vector containing in tandem the nucleotide sequence encoding the human protein and a human kinase specific for phosphorylation of that protein.

Abstract translation: 本发明提供了使用包含编码外源蛋白的核苷酸序列和对该蛋白质进行修饰的特异性酶的单一载体在宿主细胞中产生修饰的重组蛋白质的方法。 本发明还具体提供了在细菌系统中使用单一载体同时编码编码人蛋白质的核苷酸序列和对该蛋白质的磷酸化特异的人类激酶的生物质重组磷酸化人类蛋白质的方法。